Saturday 17 October 2026 Export TELA’s income statement to Excel — free account

TELA Bio, Inc.

TELA Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $80.3 million, up 15.8% from fiscal 2024. In the quarter to June 2026, revenue fell 4.49%, EPS grew 9.09%, free cash flow fell 17.7% and total debt rose 35.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

0.98 0.03 −2.97%

Follow TELA

Alert me

Market cap: $45.6M
P/E: 0.0×
Fwd P/E: −1.4×
Dividend yield: —
F-score: 3/9
Altman Z: −5.93
Beneish M: −3.31
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 4.19

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	2	2	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 41.81%

Capital & Financial Ratios $m

Market Cap 45.59

Revenue 79.91

Net Income (41.18)

Free Cash Flow (31.62)

Net Debt 25.66

Current Ratio 2.99

Debt/Equity (3.53)

P/E ratio 0.00

Fwd P/E (1.35)

P/S ratio 0.70

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 17.96%

Next Y EPS Growth 35.22%

Next Y revenue growth (0.85%)

Next 5Y EPS Growth 26.12%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 16.12%

10-year low 10-year high

EV/Sales against its own 10 years 22.82%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	47	53	51	30
Receivables	10	10	10	10
Inventory	13	13	11	11
Other	—	—	—	—
	72	78	76	54

	2023	2024	2025	Q'26
Payables	2	2	2	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	17	16	18	18

Compound Annual Growth %

	10y	5y	3y
Sales	—	34.54%	24.68%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(33.63%)	(23.87%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	19	19	—	—	—
’25	19	20	21	21	80
’24	17	16	19	18	69
’23	12	14	15	17	58
’22	8	10	11	12	41
’21	6	8	8	8	29
’20	4	4	5	6	18

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(11)	(9)	—	—	—
’25	(10)	(8)	(6)	(5)	(28)
’24	(14)	(11)	(9)	(8)	(42)
’23	(12)	(11)	(7)	(11)	(41)
’22	(10)	(12)	(8)	(11)	(41)
’21	(9)	(6)	(7)	(10)	(30)
’20	(7)	(6)	(4)	(7)	(24)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(11)	(9)	—	—	—
’25	(10)	(8)	(6)	(5)	(29)
’24	(15)	(11)	(9)	(8)	(43)
’23	(12)	(11)	(7)	(11)	(41)
’22	(11)	(12)	(8)	(12)	(43)
’21	(9)	(6)	(7)	(10)	(31)
’20	(7)	(6)	(4)	(7)	(25)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.21)	(0.20)	—	—	—
’25	(0.25)	(0.22)	(0.19)	(0.17)	(0.83)
’24	(0.23)	(0.51)	(0.42)	(0.23)	(1.33)
’23	(0.63)	(0.46)	(0.45)	(0.53)	(2.04)
’22	(0.75)	(0.88)	(0.64)	(0.52)	(2.72)
’21	(0.56)	(0.57)	(0.57)	(0.59)	(2.30)
’20	(0.63)	(0.53)	(0.53)	(0.54)	(2.23)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	10.78	5.25	11.03	5.15	4.24	2.30	0.87	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	15.05	23.55	18.00	13.70	13.18	7.84	3.10
People
People	Employees	—	—	86	89	108	123	173	166	209	150
	Revenue/emp, $m	—	0.00	0.10	0.17	0.17	0.24	0.24	0.35	0.33	0.54
Income, $m
Income, $m	Revenue	—	4	8	15	18	29	41	58	69	80
	Gross margin, %	—	59.65	45.04	62.00	63.35	64.88	67.24	69.27	67.63	68.17
	EBT	—	(21)	(21)	(22)	(29)	(33)	(44)	(47)	(38)	(39)
	EBT margin, %	—	(502.57)	(254.92)	(145.18)	(158.10)	(112.94)	(106.95)	(79.83)	(54.81)	(48.09)
	Net income	—	(21)	(21)	(22)	(29)	(33)	(44)	(47)	(38)	(39)
	Depreciation	—	1	1	1	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	—	14.54	28.05	8.75	1.41	2.04	2.55	2.56	2.43	1.71
	Earnings	—	(73.06)	(71.50)	(17.10)	(2.23)	(2.30)	(2.72)	(2.04)	(1.33)	(0.83)
	Cash flow	—	(56.05)	(67.54)	(14.45)	(1.89)	(2.10)	(2.50)	(1.79)	(1.46)	(0.60)
	Capex	—	(0.35)	(5.28)	(1.53)	(0.01)	(0.04)	(0.12)	(0.03)	(0.03)	(0.01)
	Free cash flow	—	(56.40)	(72.82)	(15.98)	(1.90)	(2.15)	(2.62)	(1.81)	(1.49)	(0.61)
	Book value	—	(370.45)	(467.32)	17.53	3.79	1.39	0.88	0.83	1.00	0.13
	Shares, m	—	0	0	2	13	14	16	23	29	47
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	0.31	0.31	1.48	10.68	6.29	4.52	2.59	1.24	0.69
	P/B	—	0.00	0.00	0.74	3.97	9.22	13.08	8.02	3.03	8.78
	EV/Sales	—	1.90	1.90	(0.04)	8.34	5.90	4.47	2.49	1.08	0.79
	EV/FCF	—	(0.91)	(0.91)	0.02	(5.60)	(5.18)	(4.15)	(3.27)	(1.64)	(2.01)
Cash, $m
Cash, $m	Operating cash flow	—	(16)	(20)	(26)	(24)	(30)	(41)	(41)	(42)	(28)
	Capex	—	0	(2)	(3)	0	(1)	(2)	(1)	(1)	0
	Free cash flow	—	(16)	(21)	(28)	(25)	(31)	(43)	(41)	(43)	(29)
Balance, $m
Balance, $m	Working capital	—	8	14	58	77	48	50	55	62	58
	Total debt	—	5	30	30	31	31	40	41	41	56
	Net debt	—	(7)	12	(24)	(44)	(12)	(2)	(6)	(12)	5
	Shareholders’ equity	—	(108)	(138)	31	49	20	14	19	28	6
Returns, %
Returns, %	ROA	—	(127.35)	(139.92)	(63.50)	(37.30)	(44.67)	(67.94)	(63.97)	(45.97)	(46.23)
	ROIC	—	0.00	0.00	(180.96)	(289.37)	(240.36)	(199.80)	(217.47)	(126.08)	(189.70)
	ROE	—	22.13	24.32	56.52	(72.00)	(96.28)	(257.51)	(281.23)	(159.87)	(223.35)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MYO Myomo, Inc.	$51.5M	— (loss-making)	— (loss-making)	+21.26% (above 0%: growing)	n/m	+80.02% (above 0%: growing)	72.13%	(19.26%)	Compare
COCH Envoy Medical, Inc.	$49.9M	— (loss-making)	— (loss-making)	−34.62% (below 0%: shrinking)	n/m	−22.44% (below 0%: shrinking)	(445.10%)	(10,919.61%)	Compare
MDAI Spectral AI, Inc.	$49.6M	— (loss-making)	— (loss-making)	−30.42% (below 0%: shrinking)	n/m	−21.86% (below 0%: shrinking)	31.58%	(122.70%)	Compare
TLIS Talis Biomedical Corporation	$46.3M	— (loss-making)	— (loss-making)	−94.01% (below 0%: shrinking)	n/m	+23.80% (above 0%: growing)	91.78%	0.00%	Compare
SRTS Sensus Healthcare, Inc.	$45.6M	— (loss-making)	— (loss-making)	−68.69% (below 0%: shrinking)	n/m	−201.65% (below 0%: shrinking)	33.58%	(138.86%)	Compare
TELA TELA Bio, Inc.	$45.6M	— (loss-making)	— (loss-making)	−4.49% (below 0%: shrinking)	n/m	−17.72% (below 0%: shrinking)	72.77%	(48.12%)
SNWV Sanuwave Health Inc.	$44.5M	3.0×	— (loss-making)	−3.13% (below 0%: shrinking)	n/m	+86.75% (above 0%: growing)	76.23%	(2.88%)	Compare
XTNT Xtant Medical Holdings, Inc.	$42.5M	— (loss-making)	— (loss-making)	−34.96% (below 0%: shrinking)	n/m	−881.96% (below 0%: shrinking)	57.88%	(39.81%)	Compare
RPID Rapid Micro Biosystems, Inc.	$42.4M	— (loss-making)	— (loss-making)	+10.91% (above 0%: growing)	n/m	−23.97% (below 0%: shrinking)	15.05%	(152.99%)	Compare
Median of peers	$45.9M	—	—	−32.52%	—	−22.15%	45.73%	(81.26%)

All 149 Medical Devices stocks →

TELA Bio, Inc. (TELA) key facts

Strength: TELA Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $80.3 million, up 15.8% from fiscal 2024.
TELA Bio, Inc. (TELA) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, TELA traded at $0.98, a market capitalization of $45.6 million.
Return on equity was −223.4% and debt-to-equity -3.53.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −5.93 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.